Printed from Voxsanity (voxsanity.com.au) — NCT06446206 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Ovarian Cancer
Phase 2 Ovarian Cancer Trial, Not Yet Recruiting
NCT06446206
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have given their full informed consent and signed a written consent form agreeing to take part in the study.
- People aged between 18 and 75 years old.
- People who have been confirmed by pathology (laboratory testing of tissue) to have epithelial ovarian cancer, epithelial fallopian tube cancer, or primary peritoneal cancer.
- People whose cancer has been staged as Stage III or Stage IV according to the 2018 FIGO (International Federation of Gynecology and Obstetrics) staging system.
- People who have received no more than 2 previous rounds of platinum-based chemotherapy, and whose cancer came back at least 6 months after their last chemotherapy treatment.
- People who have received no more than 1 previous PARP inhibitor treatment.
- People who do not carry inherited (germline) mutations in the BRCA gene (a gene linked to breast and ovarian cancer risk).
- People who have at least 1 measurable area of cancer that can be assessed using standard imaging criteria (called RECIST 1.1).
- People whose doctors expect them to survive for at least 12 weeks.
- People who have an ECOG Performance Status score of 0 or 1, meaning they are either fully active or able to carry out light activity (confirm with trial site).
- People whose organ function meets specific blood test requirements, assessed without having received blood transfusions or certain blood-boosting medications in the 14 days before starting the trial treatment, including: a neutrophil count (a type of white blood cell) of at least 1.5 x 10⁹/L; a platelet count of at least 80 × 10⁹/L; a haemoglobin level of at least 75 g/L; an albumin (a blood protein) level of at least 30 g/L; a total bilirubin level no higher than 1.5 times the upper limit of normal; liver enzyme levels (ALT and AST) no higher than 3 times the upper limit of normal, or up to 5 times if liver spread is present; a creatinine level (a kidney marker) no higher than 1.5 times the upper limit of normal; and normal blood clotting test results (INR, PT, and APTT all within 1.5 times the upper limit of normal).
- People whose blood electrolyte levels (such as sodium and potassium) are within the normal range.
- Women who could become pregnant must have had a negative pregnancy test (blood or urine) within 7 days before enrolling, and must be willing to use an appropriate method of contraception throughout the trial and for 8 weeks after the last dose of the study drug.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who are known to be allergic or have had a severe reaction to the study drug or any of its ingredients.
- People who have another cancer at the same time that cannot be cured.
- People who have active cancer spread to the brain or central nervous system that is not controlled or is causing symptoms.
- People who are pregnant, breastfeeding, or who have a positive pregnancy test (blood or urine), or people of childbearing potential who are unwilling or unable to use effective contraception until at least 6 months after the last trial treatment.
- People with diabetes that is very difficult to control, meaning blood sugar levels fluctuate widely and affect daily life, even with standard insulin treatment and frequent monitoring.
- People who have had, within the 4 weeks before the first study dose, a heart attack, severe or unstable chest pain (angina), significant heart rhythm problems, heart failure of NYHA Class 2 or above, symptomatic congestive heart failure, or blood pressure that is not controlled and is moderately or severely elevated (systolic above 160 mmHg or diastolic above 100 mmHg); also people with known coronary artery disease or a heart pumping function (left ventricular ejection fraction) below 50% (confirm with trial site for full details on heart-related criteria).
- People with a history of autoimmune disease affecting the nervous system, or moderate to severe autoimmune disease, or who have needed high doses of medications that suppress the immune system to manage their symptoms.
- People who have previously had an organ transplant or a stem cell transplant from another person.
- People who have had major surgery within the 6 weeks before starting the study drug (minor procedures such as tissue biopsies or insertion of a central line for medication delivery are generally permitted).
- People who need ongoing high-dose steroid tablets (more than 10 mg per day of prednisone or an equivalent) or other immune-suppressing medications on a continuing basis (note: steroid creams, eye drops, joint injections, nasal sprays, and inhalers are generally permitted).
- People who have had a serious infection within the 90 days before joining, such as severe pneumonia requiring hospitalisation, a bloodstream infection, or active tuberculosis (note: people with certain hepatitis B or hepatitis C markers may still be eligible depending on further blood test results — confirm with trial site).
- People with a psychiatric condition that would prevent them from giving informed consent or following the study procedures.
- People who, in the opinion of the study doctor, have any other condition that makes participation in this study unsuitable.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
The First Hospital of Jilin University
Registry
ClinicalTrials.gov
Start date
1 June 2024
Est. completion
1 June 2026
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
12-month progression-free survival rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.